MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP
Phase 2
Withdrawn
- Conditions
- Immune Thrombocytopenic PurpuraIdiopathic Thrombocytopenic Purpura
- Interventions
- Biological: BlisibimodOther: Placebo
- Registration Number
- NCT01609452
- Lead Sponsor
- Anthera Pharmaceuticals
- Brief Summary
The purpose of this study is to evaluate efficacy, safety and tolerability of blisibimod when administered on top of standard-of-care to subjects with Immune Thrombocytopenic Purpura (ITP).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- 18 to 75 years of age(male or female).
- Diagnosis of ITP according to the guidelines of the American Society of Hematology (ASH) and British Committee for Standards in Hematology.
- Platelet counts at Screening of 30 billion/L or less for subjects not on ITP medication, or 50 billion/L or less for subjects receiving stable background ITP medication.
Read More
Exclusion Criteria
- Subjects who have had a splenectomy for any reason.
- Currently receiving high-dose ITP medications, eltrombopag, romiplostim, rituximab, or investigational therapeutic agents.
- Nursing or pregnant.
- Active infection requiring hospitalization or treatment with parenteral antibiotics within the past 60 days.
- Any known history of bone marrow stem cell disorder.
- Active hepatitis B, active hepatitis C or a documented history of HIV, hepatitis B, or hepatitis C.
- Liver disease.
- Malignancy within the past 5 years.
- History of active tuberculosis (TB) or history of TB infection.
- Subject has not yet completed at least 3 months or 5 half-lives (whichever is longer) since ending other investigational study.
- History of congenital immunodeficiency.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Blisibimod Blisibimod - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Achievement of a durable platelet response of 50 billion platelets per liter or higher over the last weeks of treatment. 24 weeks
- Secondary Outcome Measures
Name Time Method Biomarker changes from baseline. baseline to 24 weeks Change in background corticosteroid dose. baseline to 24 weeks Time to treatment failure. 24 weeks Change in bleeding risk. baseline to 24 weeks Achievement of a durable platelet count of 50 billion platelets per liter or higher over the last weeks of treatment under conditions of decreased concomitant steroid medication. 24 weeks Achievement of a transient improvement in platelet count of 50 billion platelets per liter or higher at any 4 weeks of the treatment period. 24 weeks Percentage of subjects requiring rescue therapy. 24 weeks Safety profile (AEs, vitals signs, labs) 24 weeks